UniQure paused mid- and high-dose cohorts in its Fabry gene therapy trial after two patients at 4x10^13 gc/kg experienced grade 3 liver enzyme elevations, the company said in a safety update. The halt affects dose-escalation plans and will prompt protocol amendments and safety monitoring changes while investigators investigate causality and management procedures. Separately, Aro Biotherapeutics presented data in Pompe disease that the market is parsing for durability and safety signals. The UniQure pause underscores persistent challenges for systemic AAV dosing, liver tolerability and vector-host interactions that regulators have highlighted in recent guidance. Companies developing in vivo gene therapies are likely to re-evaluate dose selection, hepatic monitoring strategies, and risk mitigation plans as a consequence.